Skip to content
★ Sign in to follow
CG MedTech Co.,Ltd. logo

CG MedTech Co.,Ltd. Stock: price and insider trades · South Korea

시지메드텍

KR·Mcap ₩96.7BHealth Care

No insider purchase over the last 90 days. The latest, by 시지바이오, was filed 19 Jan 2026.

CG MedTech Co.,Ltd.: what insiders have been doing

Every trade that managers of CG MedTech Co.,Ltd. disclose to DART (FSS) is tracked on this page. The company sits in the Health Care sector. 1 insider has disclosed 5 filings since 22 October 2025.

On the market, 1 insider bought (2 purchases) while 1 insider sold (3 sales). The totals exclude 5 filings filed without an amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price.

Compared with its exchange (2,650 companies, median 7 filings), a count of 5 filings is below the norm. Since 2021, the database holds 43 purchases and 3 sales by insiders of the company.

The last purchase on record was published on 19 January 2026, which is 295 days ago. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.

For comparison within the same sector, see the insider buying recorded at UCB. Source: insider filings from DART (FSS). Past trades are no guide to future returns.

Insider Decl.
80
Thresholds
n/a
Buy Volume
€24M
43 ops. · all time
Sell Volume
n/a
3 ops. · all time

Who traded when

BuySale
시지바이오2 buys3 sales

Since the insiders bought

  • Filed 16 Feb 2024 · 998 days ago · €24.2M
    -15.3%
    Entry ₩5,900 · Close at T+365 ₩4,995

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 12,485 of 26,911 companies
53.4
score / 100
Value
40
Quality
67
FCF yld-11%
Earn yld7.5%
EV/EBITDA17.5x
ROE7.1%
Gross mgn45%
Net mgn14%
Debt/EBITDA0.8x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

₩4,680
Analyst consensus
·
Income statement
Revenue₩47.2B
Gross profit₩21.2B45% margin
EBITDA₩5.2B11% margin
Net income₩6.5B12.8% margin
Valuation
Beta-0.10
Balance sheet & cash
Market cap₩96.7B
Total debt₩4.3B
Free Cash Flow-₩9.3B
Debt / Equity21%
Profitability & ownership
ROE7.1%
ROA1.0%
% insiders40.5%
% institutions3.8%
Last declaration on 15 October 2026
Declarations83 total
  • ▼
    10%이상주주Executives(filed)
    0DART
    35,035,560 sharesShareKRXDART:20261015000305
  • Other
    Other(filed)
    0DART
  • Other
    Other(filed)
    0DART
  • Other
    Other(filed)
    0DART
  • ▲
    Executives
    0DART
    41,730,450 sharesKRXDART:20260119000049
    Canonical exit: 12 Apr 2026 (T+90)
  • ▼
    Executives
    0DART
    41,730,450 sharesKRXDART:20260119000047
  • ▲
    10%이상주주Executives(filed)
    0DART
    41,724,450 sharesShareKRXDART:20260119000050
    Canonical exit: 19 Apr 2026 (T+90)
  • ▼
    10%이상주주Executives(filed)
    0DART
    41,724,450 sharesShareKRXDART:20260119000048
  • ▲
    -Executives(filed)
    0DART
    9,174,311 sharesShareKRXDART:20241106000181
    Canonical exit: 4 Feb 2025 (T+90)
  • ▲
    Executives
    0DART
    9,158,891 sharesKRXDART:20241106000178
    Canonical exit: 29 Jan 2025 (T+90)
  • ▲
    대표이사Executives
    0DART
    ShareKRXDART:20240617000320
    Canonical exit: 9 Sept 2024 (T+90)
  • ●
    Executives
    Executives(filed)
    0DART
  • ▲
    대량보유자Executives
    0DART
    14,007,434 sharesKRXDART:20240216000714
    Canonical exit: 7 May 2024 (T+90)
  • ▲
    Executives
    35B KRW10DART
    27,986,014 shares@ ₩1,234.2594100.0% of flowShareKRXDART:20240216000672
    Canonical exit: 7 May 2024 (T+90)
  • ●
    Executives
    Executives(filed)
    0DART
  • ▲
    Executives
    0DART
    9,158,891 sharesKRXDART:20231208000659
    Canonical exit: 28 Feb 2024 (T+90)
  • ▲
    Executives
    0DART
    9,158,891 sharesKRXDART:20231207000191
    Canonical exit: 28 Feb 2024 (T+90)
  • ▲
    Executives
    0DART
    9,158,891 sharesKRXDART:20230901000413
    Canonical exit: 9 Oct 2022 (T+90)
  • ▲
    Executives
    0DART
    9,158,891 sharesKRXDART:20230810000700
    Canonical exit: 15 Oct 2023 (T+90)
  • ▲
    Executives(filed)
    0DART
    9,158,891 sharesKRXDART:20230407000682
    Canonical exit: 6 Jul 2023 (T+90)
  • ●
    대표이사Executives(filed)
    0DART
    ShareKRXDART:20230327000716
  • ●
    대표이사Executives(filed)
    0DART
    ShareKRXDART:20230327000701
  • ●
    대표이사Executives(filed)
    0DART
    ShareKRXDART:20230327000697
  • ●
    Executives
    Executives(filed)
    0DART
  • ▲
    Related company / holdingExecutives(filed)
    €231kest.0DART
    52,116 sharesKRXDART:20230110000529
    Canonical exit: 10 Apr 2023 (T+90)

25 of 83 declarations

About CG MedTech Co.,Ltd.

시지메드텍 is a company operating in the healthcare and pharmaceutical sector, listed on the XKRX market. It specializes in the development of innovative medical technologies.